Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  • Maria Thomsen
  • Christian Kersten
  • Halfdan Sorbye
  • Eva Skovlund
  • Bengt Glimelius
  • Per Pfeiffer
  • Johansen, Julia Sidenius
  • Elin H Kure
  • Tone Ikdahl
  • Kjell Magne Tveit
  • Thoralf Christoffersen
  • Tormod Kyrre Guren

Objectives: The aim was to explore the prognostic significance of IL-6 and markers of systemic inflammatory response (SIR), in particular C-reactive protein (CRP), in metastatic colorectal cancer (mCRC) patients, in the total study population and according to RAS and BRAF mutation status. Results: High levels of pretreatment serum IL-6 or CRP were associated with impaired outcome, in terms of reduced PFS and OS. Patients with low versus high serum IL-6 levels had median OS of 26.0 versus 16.6 months, respectively (P < 0.001). Stratified according to increasing CRP levels, median OS varied from 24.3 months to 12.3 months, (P < 0.001). IL-6 and CRP levels affected overall prognosis also in adjusted analyses. The effect of IL-6 was particularly pronounced in patients with BRAF mutation (interaction P = 0.004). Materials and Methods: IL-6 and CRP were determined in pre-treatment serum samples from 393 patients included in the NORDIC-VII trial, in which patients with mCRC received first line treatment. The effect of serum IL-6 and CRP on progressionfree survival (PFS) and overall survival (OS) was estimated. Conclusions: High baseline serum consentrations of IL-6 or CRP were associated with impaired prognosis in mCRC. IL-6 and CRP give independent prognostic information in addition to RAS and BRAF mutation status.

Original languageEnglish
Issue number46
Pages (from-to)75013-75022
Number of pages10
Publication statusPublished - 2016

    Research areas

  • CRP, IL-6, mCRC, Prognostic biomarker, Survival

Number of downloads are based on statistics from Google Scholar and

No data available

ID: 180937829